CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 187 filers reported holding CRISPR THERAPEUTICS AG in Q3 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $11,024,000 | -25.7% | 150,000 | -57.1% | 0.09% | -30.7% |
| Q1 2020 | $14,844,000 | -30.4% | 350,000 | 0.0% | 0.13% | -11.8% |
| Q4 2019 | $21,317,000 | -7.2% | 350,000 | -37.5% | 0.14% | -16.8% |
| Q3 2019 | $22,969,000 | -2.5% | 560,367 | +12.1% | 0.17% | +13.1% |
| Q2 2019 | $23,550,000 | -9.1% | 500,000 | -31.0% | 0.15% | -21.5% |
| Q1 2019 | $25,897,000 | -27.5% | 725,000 | -42.0% | 0.20% | -25.6% |
| Q4 2018 | $35,713,000 | -20.9% | 1,250,000 | +22.7% | 0.26% | -1.9% |
| Q3 2018 | $45,175,000 | -10.7% | 1,018,594 | +18.3% | 0.27% | -14.4% |
| Q2 2018 | $50,575,000 | +71.5% | 860,700 | +33.4% | 0.31% | +52.9% |
| Q1 2018 | $29,483,000 | +46.2% | 645,000 | -24.9% | 0.20% | +24.4% |
| Q4 2017 | $20,160,000 | – | 858,602 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |